Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Recurrence 1Medulloblastoma 1Carcinoma, Basal Cell 1

Interventions

HhAntag691 11sonidegib 5cemiplimab 5methyl 5-aminolevulinate 4daromun 4Imiquimod 3IPI-926 3gusacitinib 2Photochemotherapy 2Drug Evaluation 23-ingenyl angelate 2tozuleristide 1silmitasertib 1pembrolizumab 1TAK-441 1NVP-LEQ506 1MAPRE1 protein, human 1Intravital Microscopy 1Interleukin-2 1Injections 1IFL protocol 1Folfox protocol 1Capecitabine 1Bevacizumab 1BO-112 1BMS-833923 1BF-200 ALA 1Ascorbic Acid 1Aminolevulinic Acid 11-phenyl-3,3-dimethyltriazene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Basal Cell × NVP-LEQ506 × Clear all
NCT01106508 2020-12-17

A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
57 enrolled
CNSDermatologic

Carcinoma, Basal Cell, Medulloblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡